Melanotan II Alternatives

PT-141, generic name bremelanotide and sold as Vyleesi, is a melanocortin peptide and a cyclic analog of alpha-MSH that works in the brain to boost sexual desire. It is genuinely FDA approved: in June 2019 it became the first on-demand treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label for low libido and erectile dysfunction in men.

TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.

Tirzepatide is a single peptide that activates two receptors at once: GIP and GLP-1, the two main incretin hormones your gut releases after eating. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. Like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.

CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.

GLOW (sometimes sold as Glow Blend) is a marketing name for a three-peptide cocktail: GHK-Cu (a copper-binding tripeptide), BPC-157, and TB-500. It is pitched for skin rejuvenation, collagen support, and tissue healing, usually as a single injectable blend from compounding clinics or research suppliers. None of the three peptides is FDA-approved for these uses, and the GLOW combination has never been studied as a product in any clinical trial.